A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results